Ovarian Cancer

On November 14, 2022, the FDA accelerated the approval of mirvetuximab soravtansine-gynx (Elahere; ImmunoGen), an intravenous (IV) folate receptor alpha (FRα)-directed antibody and microtubule inhibitor conjugate, for the treatment of adults with FRα-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer after 1 to 3 previous systemic treatments, regardless of previous use of bevacizumab (Avastin). Read More ›

In 2021, the COVID-19 pandemic continued to impact the practice of medicine and dissemination of treatment advances presented in scientific forums. Read More ›

Results of the primary analysis of the phase 3b OPINION study supported the use of olaparib maintenance therapy in patients with nongermline BRCA1/2-mutated platinum-sensitive relapsed ovarian cancer. Read More ›

The final overall survival analysis of the phase 2 LIGHT study indicates that olaparib therapy in patients with platinum-sensitive relapsed ovarian cancer provides overall survival benefit across patient cohorts, regardless of BRCA mutation and homologous recombination deficiency status, with a safety profile consistent with that previously described. Read More ›

Results of the phase 2 EFFORT study support the efficacy of adavosertib, with and without olaparib, in patients with poly (ADP-ribose) polymerase inhibitor–resistant ovarian cancer, with manageable adverse events. Read More ›

Results of the PAOLA-1/ENGOT-ov25 study demonstrated sustained progression-free survival benefit with the addition of maintenance olaparib to bevacizumab, compared with placebo and bevacizumab in homologous recombination deficiency-positive patients, irrespective of International Federation of Gynecology and Obstetrics stage and residual disease after up-front surgery. Read More ›

Results of the subgroup analysis of the ARIEL4 study suggest that heavily pretreated patients with advanced relapsed ovarian carcinoma harboring a BRCA1/2 mutation derive progression-free survival benefit from rucaparib treatment across all platinum-sensitivity subgroups. Read More ›

Five-year follow-up results of the SOLO1 trial indicate that 2 years of maintenance olaparib provides sustained progression-free survival benefit in patients with newly diagnosed advanced ovarian cancer harboring BRCA1 and/or BRCA2 mutations, with no emergence of new safety signals. Read More ›

Secondary efficacy data and subgroup analyses from the LIGHT study indicate that olaparib monotherapy was most effective in BRCA-mutated cohorts of patients with platinum-sensitive relapsed ovarian cancer. Read More ›

Results of the ORZORA trial indicate that patients with platinum-sensitive relapsed ovarian cancer derived progression-free survival benefit from maintenance olaparib, irrespective of somatic or germline BRCA mutation status. Read More ›